Jefferies Group LLC Immuno Gen, Inc. Call Options Transaction History

Jefferies Group LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $71,250 - $112,500	-15,000 Closed	0 $0
Q2 2021 Sep 21, 2023	BUY	$5.79 - $8.6 $86,850 - $129,000	15,000 New	15,000 $98,000
Q2 2021 Aug 20, 2021	SELL	$5.79 - $8.6 $8.6 Million - $12.8 Million	-1,485,000 Reduced 99.0%	15,000 $99,000
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $8.69 Million - $12.9 Million	1,500,000 New	1,500,000 $99,000
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $78,840 - $144,540	-43,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $105,558 - $258,858	43,800 New	43,800 $119,000
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $137,900 - $339,500	-35,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $162,540 - $212,814	-18,900 Reduced 35.06%	35,000 $331,000
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $513,128 - $654,885	53,900 New	53,900 $524,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.